Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Adding a second HER2 targeted medicine may lower chance of invasive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 1094

Dr Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Dr Gunter von Minckwitz presents, at a press conference at ASCO 2017, findings from a phase III clinical trial of 4,805 women with HER2-positive breast cancer that suggests that adding a second HER2 targeted medicine, pertuzumab, to standard of care trastuzumab after surgery may help to lower the chance of invasive breast cancer to some women. 

Read the news story and watch the video interview for more. 

Related videos

follow us

SIOG e-learning July 2017

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation